A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

September 16, 2017

Study Completion Date

September 19, 2017

Conditions

NASH

Interventions

DRUG

EDP 305

Each subject will receive a single dose of EDP 305 on Day 1.

Trial Locations (3)

American Research Corporation at The Texas Liver Institute, San Antonio

Pharmaceuticals Research Associates, Prague

Summit SRO, Bratislava